Pharming Group N.V. 6-K Filing
Ticker: PHAR · Form: 6-K · Filed: Apr 2, 2026 · CIK: 0001828316
| Field | Detail |
|---|---|
| Company | Pharming Group N.V. (PHAR) |
| Form Type | 6-K |
| Filed Date | Apr 2, 2026 |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Pharming Group N.V. (ticker: PHAR) to the SEC on Apr 2, 2026.
How long is this filing?
Pharming Group N.V.'s 6-K filing is 2 pages with approximately 470 words. Estimated reading time is 2 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 9.1 · Accepted 2026-04-02 06:10:50
Filing Documents
- pharminggroupannouncesthef.htm (6-K) — 20KB
- logo_greyxoriginalxa.jpg (GRAPHIC) — 112KB
- 0001828316-26-000017.txt ( ) — 163KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated April 2, 2026. EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group announces the filing of its 2025 Annual Report and Form 20-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By s Fabrice Chouraqui Name Fabrice Chouraqui Title CEO Date April 2, 2026 Pharming Group announces the filing of its 2025 Annual Report and Form 20-F Leiden, the Netherlands, April 2, 2026 Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam PHARM Nasdaq PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. The Annual Report is available at annualreport.pharming.com and under InvestorsFinancial documents on the Pharming.com website. The Company also announced the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The 2025 Annual Report on Form 20-F can be found under InvestorsSEC filings on Pharming.com and through the SEC website once it has been filed. About Pharming Group N.V. Pharming Group N.V. (Euronext Amsterdam PHARMNasdaq PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S. For more information, visit www.pharming.com and find us on LinkedIn. For further public information, contact Investor Relations Michael Levitan, VP Investor Relations Corporate Communications T +1 (908) 705 1696 E investorpharming.com Media Relations Global Saskia Mehring, Corporate Communications Manager T +31 6 28 32 60 41 E media.relationspharming.com U.S. Ethan Metelenis (Precision AQ on behalf of Pharming) T +1 (917) 882-9038 Netherlands Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming) T +31 6 53 81 64 27